Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 1.00 |
| ▸ | ALB | P02768 | 3/20 | 0.64 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine 5'-Triphosphate SCHEMBL30480833 | 1.00 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| Emtricitabine 5'-Triphosphate SCHEMBL14354587 | 1.00 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL4373149 | 0.90 | POLG (0.82) | POLGALBCACNA1FLMNAMAPT | |
| Lamivudine Triphosphate SCHEMBL12595501 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL13199313 | 0.83 | POLG (0.71) | POLGALBP2RY2P2RY4P2RY6 | |
| Lamivudine Triphosphate SCHEMBL14354589 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| Lamivudine Triphosphate SCHEMBL2223243 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL6909903 | 0.83 | POLG (0.71) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492503 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL8409011 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240262857-A1 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | EMORY UNIVERSITY | 2024-08-08 | — | — | US | disclosed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | EMORY UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | EMORY UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-05-31 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | ANDERSON KAREN S (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2393815-A2 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | RFS Pharma, LLC. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010091386-A2 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010068708-A2 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2155771-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS Pharma, LLC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143846-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | POLG 721/4885ALB 149/4885CACNA1F 4168/4885 |
| US-20100279969-A1 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | CDA, APOBEC3G, DIMT1 | POLG 173/4885ALB 4077/4885CACNA1F 3685/4885 |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | NAMPT, NAPRT, DNTT | POLG 175/4885ALB 4709/4885CACNA1F 4420/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | POLG 1732/4885ALB 1912/4885CACNA1F 4105/4885 |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, ENTPD5, ADA | POLG 1272/4885ALB 3769/4885CACNA1F 4234/4885 |
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | DCTD, ENTPD5, PNP | POLG 980/4885ALB 2988/4885CACNA1F 4557/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | POLG 433/4885ALB 357/4885CACNA1F 3738/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | POLG 1772/4885ALB 4862/4885CACNA1F 3868/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | POLG 415/4885ALB 239/4885CACNA1F 3407/4885 |
| US-20240262857-A1 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | NSUN2, RBM28, HNRNPC | POLG 1757/4885ALB 3179/4885CACNA1F 4126/4885 |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | SAMHD1, PNP, NUDT1 | POLG 3683/4885ALB 2989/4885CACNA1F 4358/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | POLG 3683/4885ALB 2989/4885CACNA1F 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.